Open Call SC1-PM-16-2017: In-Silico Trials for Developing and Assessing Biomedical Products

European Commission Proposals will develop innovative in-silico trials for designing, developing and assessing drugs, radiation and other biomedical and bioactive products. They will build on comprehensive biological and biomedical knowledge management and advanced modelling paradigms in order to be able to simulate the individual human physiology and physiopathology at the biological levels relevant for the biomedical product under study (at the cell level, tissue level or organism level) and the interaction with the product, thus taking into account the variability among individuals (for example, molecular pathways, cellular microenvironments, microbiota, genetics, gender characteristics, behaviours, comorbidities, development, diet). Virtual populations of individual patients will be built for simple or composite diseases, for example, from the patient-specific models by variations of different parameters and will allow simulating the action of the products and predicting the treatments outcomes in order to develop a personalised medicine approach. The proposed in-silico trials will be the result of a multidisciplinary effort (e.g. within the fields of computational modelling, systems biology, tissue mechanics, biology, pharmaceutics, medicine) and will also explore and inform of the reasons of fails and suggest improvements. To help establishing such computer simulated trials, measures for validation (human trials, animal studies, validation in cell cultures) of the in-silico models shall also be included in the proposed projects. The benefit for human health, environment and animal welfare should be analysed and quantified. Contact with regulators and consideration of the regulatory framework issues are highly recommended.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Planned opening date: 08 November 2016

Deadline Date: 14 March 2017 17:00:00

Type of action: RIA Research and Innovation action.

For topic conditions, documents and submission service, please visit:
https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/3062-sc1-pm-16-2017.html

PS: Find your partners or consortia preparing a project proposal
If you are working on Horizon 2020 research project proposals and you would be interested in a SME partner from Germany, please contact us, we are ready to share our experience, expertise and knowledge. If you need help to identify a potential partner with particular competences, facilities or experience, please explore and join our project, (HEALTH IT) SPACE, at www.healthitspace.eu.

Most Popular Now

ChatGPT can Produce Medical Record Notes…

The AI model ChatGPT can write administrative medical notes up to ten times faster than doctors without compromising quality. This is according to a new study conducted by researchers at...

Alcidion and Novari Health Forge Strateg…

Alcidion Group Limited, a leading provider of FHIR-native patient flow solutions for healthcare, and Novari Health, a market leader in waitlist management and referral management technologies, have joined forces to...

Can Language Models Read the Genome? Thi…

The same class of artificial intelligence that made headlines coding software and passing the bar exam has learned to read a different kind of text - the genetic code. That code...

Study Shows Human Medical Professionals …

When looking for medical information, people can use web search engines or large language models (LLMs) like ChatGPT-4 or Google Bard. However, these artificial intelligence (AI) tools have their limitations...

Advancing Drug Discovery with AI: Introd…

A transformative study published in Health Data Science, a Science Partner Journal, introduces a groundbreaking end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field...

Bayer and Google Cloud to Accelerate Dev…

Bayer and Google Cloud announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will...

Shared Digital NHS Prescribing Record co…

Implementing a single shared digital prescribing record across the NHS in England could avoid nearly 1 million drug errors every year, stopping up to 16,000 fewer patients from being harmed...

Ask Chat GPT about Your Radiation Oncolo…

Cancer patients about to undergo radiation oncology treatment have lots of questions. Could ChatGPT be the best way to get answers? A new Northwestern Medicine study tested a specially designed ChatGPT...

Wanted: Young Talents. DMEA Sparks Bring…

9 - 11 April 2024, Berlin, Germany. The digital health industry urgently needs skilled workers, which is why DMEA sparks focuses on careers, jobs and supporting young people. Against the backdrop of...

North West Anglia Works with Clinisys to…

North West Anglia NHS Foundation Trust has replaced two, legacy laboratory information systems with a single instance of Clinisys WinPath. The trust, which serves a catchment of 800,000 patients in North...

Can AI Techniques Help Clinicians Assess…

Investigators have applied artificial intelligence (AI) techniques to gait analyses and medical records data to provide insights about individuals with leg fractures and aspects of their recovery. The study, published in...

AI Makes Retinal Imaging 100 Times Faste…

Researchers at the National Institutes of Health applied artificial intelligence (AI) to a technique that produces high-resolution images of cells in the eye. They report that with AI, imaging is...